Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNxxxxxxxx (where xxxxxxx represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTxxxxxxxx (where xxxxxxx represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGEN-WERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (Penzburg, Germany; Vienna, Austria)

Spontaneous In Vitro Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (Grenoble, France)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (Cardiff, UK; Beijing, China)

Spontaneous In Vitro Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, D. SCHMODT, I. GRBAC, A. KYRIAKOPOULOS (Berlin, Germany)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Identification of Serpin (α-1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOV, M.V. KISELEVSKI, T. EFFERTH (Moscow, Russia; Mainz, Germany)

DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDE, E. BLOMQVIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India)


Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study. G.P. STATHOPOULOS, S.K. RIGATOS, J. STATHOPOULOS (Athens, Greece) ............................................. 1317

Primary Pericardial Mesothelioma in an Asbestos-exposed Patient with Previous Heart Surgery. C. RIZZARDI, E. BARRESI, A. BROLLO, P. CASSETTI, M. SCHNEIDER, M. MELATO (Trieste; Gorizia, Italy) ........... 1323

Review: Clear Cell Carcinoma of the Endometrium: A Biological and Clinical Enigma. A. GADDUCCI, S. COSIO, N. SPIRITO, L. CIONINI (Pisa, Italy) ........................................................................................................... 1327


Oestrogen and Progesterone Receptor Expression in Patients with Adenocarcinoma of the Uterine Cervix and Correlation with Various Clinicopathological Parameters. K. BODNER, P. LAUBICHLER, O. KIMBERGER, K. CZERWENKA, R. ZEILLINGER, B. BODNER-ADLER (Vienna, Austria; Al Ain, United Arab Emirates) .... 1341

Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC. B.C. DANNER, V.N. DIDILIS, S. WIEMEYER, T. STOJANOVIC, J. KITZ, A. EMMERT, L. FÜZESI, F.A. SCHÖNDUBE (Göttingen, Germany) ............................................................................................................. 1347

Antimicrobial Central Venous Catheters in Oncology: Efficacy of a Rifampicin–Miconazole-releasing Catheter. J.M. SCHIERHOLZ, K. NAGELSDRICH, M. NAGELSDRICH, R. LEFFERING, N. YÜCEL, J. BEUTH (Unterach, Austria; Cologne; Coesfeld, Germany) ........................................................................................................................... 1353

Possible Associations of APE1 Polymorphism with Susceptibility and HOGG1 Polymorphism with Prognosis in Gastric Cancer. E. CANBAY, B. AGACHAN, M. GULLUOGLU, T. ISBIR, E. BALIK, S. YAMANER, T. BULUT, C. CACINA, I.Y. ERALTAN, A. YILMAZ, D. BUGRA (Istanbul, Turkey) ............. 1359

Factors Affecting Bone Marrow Toxicity Following Administration of Carboplatin and Paclitaxel in Patients with Non-small Cell Lung Cancer. A.K. GANTI, F.R. LOBERIZA JR., A. KESSINGER (Omaha, NE, USA) ...... 1365

Association Between Malaria Incidence and All Cancer Mortality in Fifty U.S. States and the District of Columbia. S. LEHRER (New York, NY, USA) ....................................................................................................................... 1371

ABSTRACTS OF THE 20th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO), Rome, June 23-25, 2010 .................................................................................................................. 1375

Erratum ........................................................................................................................................................................ 1545

* Reviews (pages 1065, 1093, 1169, 1301, 1327)

Inhibition of MAPK/ERK, PKC and CaMKII Signaling Blocks Cytolysin-induced Human Glioma Cell Death. R.C. SOLETTI, T. ALVES, J. VERNAL, H. TERENZI, G. ANDERLUH, H.L. BORGES, N.H. GABILAN, V. MOURA-NETO (Rio de Janeiro; Florianópolis, Brazil; Ljubljana, Slovenia)......................... 1209

Increased Serum Progesterone and Estradiol Correlate to Increased COX-2 Tissue Expression in Cervical Intraepithelial Neoplasia. R. SAMIR, T. TOT, A. ASPLUND, G. PEKAR, D. HELLBERG (Falun; Uppsala, Sweden) ............................................................ 1217

Glutathione Modulators Reverse the Pro-tumour Effect of Growth Factors Enhancing WiDr Cell Response to Chemotherapeutic Agents. M. CARAMÉS, A. ALONSO-VARONA, I. GARCÍA-ALONSO, T. PALOMARES (Leioa, Vizcaya, Spain) .......................................................... 1223

The Screening of Viral Risk Factors in Tongue and Pharyngolaryngeal Squamous Carcinoma. Y. ZHENG, P. XIA, H.-C. ZHENG, H. TAKAHASHI, S. MASUDA, Y. TAKANO (Toyama; Takaoka, Japan; Shenyang, P.R. China) .................................................................................. 1233

Y-Box-binding Protein-1 is a Potential Novel Tumour Marker for Neuroblastoma. R. WACHOWIAK, S. THIELITGES, T. RAWNAQ, J.T. KAIFF, H. FIEGEL, R. METZGER, A. QUAA, P.R. MERTENS, H. TILL, J.R. IZBICKI (Leipzig; Hamburg; Frankfurt; Magdeburg, Germany) .......................................................... 1239

Synthesis, Radiolabeling and In Vivo Tissue Distribution of an Anti-Oestrogen Glucuronide Compound, $^{99m}$Tc-TOR-G. F.Z. BIBER MUFTULER, P. UNAK, S. YOLCU, A. YURT KILCAR, C. ICHEDEF, H. ENGINAR, S. SAKARYA (Bornova, Izmir; Aydin, Turkey) .................................................. 1243

Clinical Studies

A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors. E. DUGAN, R. TRUAX, K.L. MEADOWS, A.B. NIXON, W.P. PETROS, J. FAVARO, N.H. FERNANDO, M.A. MORSE, G.C. BLOBE, H.I. HURWITZ (Durham, NC; Morgantown, WV, USA) .............. 1251

Treatment with Vaginal Progesterone in Women with Low-grade Cervical Dysplasia: A Phase II Trial. L. HEFLER, C. GRIMM, C. TEMPFER, A. REINTHALLER (Vienna, Austria) .................................................................................... 1257

Unique SNP in CD44 Intron 1 and its Role in Breast Cancer Development. J. ZHOU, P.S. NAGARKATTI, Y. ZHONG, K. CREEK, J. HANN, M. NAGARKATTI (Columbia, SC, USA) ................................................................. 1263

A Case of Anaplastic Thyroid Cancer with Long-term Survival. H. KOUSIS, M. MARUZZO, A. SCOLA, E.C. IDE, A. FASSINA, G. MARIONI, O. LORA, L. CORTI, P. KARACHONTZITI, A. JIRILLO (Padua; Mestre, Italy; Athens, Greece) .................................................................................. 1273

Cyclin D1b in Human Breast Carcinoma and Coexpression with Cyclin D1a Is Associated with Poor Outcome. V.G. ABRAMSON, A.B. TROXEL, M. FELDMAN, C. MIES, Y. WANG, L. SHERMAN, S. MCNALLY, A. DIEHL, A. DEMICHELE (Philadelphia, PA, USA) .................................................................................... 1279

Detection of HER2 Amplification Using the SISH Technique in Breast, Colon, Prostate, Lung and Ovarian Carcinoma. M.T. RAMIERI, R. MURARI, C. BOTTE, P. ZICA, G. ZOTTI, P.L. ALO (Rome, Italy) ...... 1287

Venous Coupler for Free-Flap Anastomosis: Outcomes of 1,000 Cases. W.M. ROZEN, I.S. WHITAKER, R. ACOSTA (Parkville, Victoria, Australia; Swansea, UK; Uppsala, Sweden) ..................................................................................... 1293

Transient Increase in Serum Thymidine Kinase 1 within One Week after Surgery of Patients with Carcinoma. Z. LI, Y. WANG, J. MA, J. HE, J. ZOU, E. HE, S. SKOG (Beijing; Shenzhen, P.R. China) ................. 1295

Contents continued on the preceding page
Gene Expression Analysis by cDNA Microarray in Oral Cancers from Two Western Populations. M.L.S. LUNDE, S. WARNAKULASURIYA, L. SAND, J.M. HIRSCH, E.N. VASSTRAND, S.O. IBRAHIM (Bergen, Norway; London, UK; Uppsala, Sweden) ................................................................. 1083

* Review: Role of Regulatory T-cells in H. pylori-induced Gastritis and Gastric Cancer. A. KANDULSKI, P. MALFERTHEINER, T. WEX (Magdeburg, Germany) ................................................................. 1093


Expression of Bone Morphogenetic Protein 7 in Lung Cancer and its Biological Impact on Lung Cancer Cells. J. CHEN, L. YE, F. XIE, Y. YANG, L. ZHANG, W.G. JIANG (Beijing, P.R. China; Cardiff, UK) ................... 1113

A Simple and Effective Method to Analyze Membrane Proteins by SDS-PAGE and MALDI Mass Spectrometry. F. DI GIROLAMO, M. PONZI, M. CRESCENZI, J. ALESSANDRONI, F. GUADAGNI (Rome, Italy) ...... 1121


Changes in Cell-Surface Peptidase Activity in Papillary Renal Cell Carcinoma. L. BLANCO, I. PEREZ, B. SANZ, J. GIL, J.I. LÓPEZ, A. UGALDE, A. VARONA, G. LARRINAGA (Leioa; Cruces/Barakaldo; Bilbao, Spain) ................................................................................................................................. 1137


Chronic Exposure of Colorectal Cancer Cells in Culture to Fluoropyrimidine Analogs Induces Thymidylate Synthase and Suppresses p53. A Molecular Explanation for the Mechanism of 5-FU Resistance. P.R. SUBBARAYAN, M. SARKAR, G. NELSON, E. BENITEZ, S. SINGHAL, B. ARDALAN (Miami, FL, USA) ................................................................................................................................. 1149

Arsenic Trioxide Suppresses Thymidylate Synthase in 5-FU-resistant Colorectal Cancer Cell Line HT29 In Vitro Re-sensitizing Cells to 5-FU. P.R. SUBBARAYAN, K. LEE, B. ARDALAN (Miami, FL, USA) ............................. 1157

ALCAM, Activated Leukocyte Cell Adhesion Molecule, Influences the Aggressive Nature of Breast Cancer Cells, a Potential Connection to Bone Metastasis. S. DAVIES, W.G. JIANG (Cardiff, UK) .................... 1163

* Review: Gamma-glutamyltransferase of Cancer Cells at the Crossroads of Tumor Progression, Drug Resistance and Drug Targeting. A. CORTI, M. FRANZINI, A. PAOLICCHI, A. POMPELLA (Pisa, Italy) ................................. 1169


Contents continued on the preceding page